Cost-Effectiveness of Fibromyalgia Treatments: Duloxetine 120mg Shows Promise

Duloxetine 120 mg demonstrated the greatest economic value in the treatment of fibromyalgia compared to other commonly used therapies, including amitriptyline and pregabalin, according to a study published in JAMA Network Open. The analysis considered both direct medical costs and broader societal costs, such as lost productivity.

Study Findings

Researchers at the University of South Carolina College of Pharmacy used a Markov cohort state transition model to assess the lifetime cost, quality-adjusted life years (QALYs) and cost-effectiveness of various fibromyalgia treatments. The treatments evaluated included different dosages of amitriptyline, pregabalin, duloxetine, and milnacipran.

The study found that duloxetine 120 mg yielded increased QALYs compared with amitriptyline, with an incremental cost-effectiveness ratio of $1,536 per QALY. Notably, duloxetine 120 mg was found to be more cost-effective than pregabalin 450 mg across multiple parameters.

When societal costs were factored in, both duloxetine 120 mg and pregabalin 450 mg showed cost savings compared to amitriptyline. But, amitriptyline remained more effective and less costly than milnacipran, lower doses of pregabalin and duloxetine, and no treatment at all.

The incremental net monetary benefit at a willingness-to-pay threshold of $100,000 for duloxetine 120 mg was $40,375 from a healthcare payer perspective and $70,063 from a societal perspective. For pregabalin 450 mg, the incremental net monetary benefit at the same threshold was $21,211 and $40,190, respectively.

Real-World Considerations

Experts emphasize that these findings should be interpreted in the context of how fibromyalgia is typically managed in clinical practice. Many patients receive combination therapy, utilizing several of these agents simultaneously, which was not fully accounted for in the study’s model.

Individual Medication Profiles

• Amitriptyline: Commonly used to improve sleep and reduce pain, but can cause side effects like dry mouth and oversedation.
• Duloxetine: May offer the highest utility for managing both pain and depression associated with fibromyalgia, but can cause nausea and be poorly tolerated by some patients.
• Pregabalin: Often associated with tolerability issues, particularly at higher doses.
• Milnacipran: Poorly tolerated and has limited access due to its cost and lack of generic alternatives in the United States.

Beyond Standard Treatments

Clinicians may also consider other options not included in the study, such as gabapentin, other tricyclic antidepressants, and cyclobenzaprine, based on individual patient needs and responses.

Key Takeaways

• Duloxetine 120 mg appears to be the most cost-effective treatment option for fibromyalgia when considering both healthcare and societal costs.
• Amitriptyline remains a viable option, particularly when cost is a major concern.
• Combination therapy is common in clinical practice and was not fully evaluated in this study.
• Individual patient tolerance and response should guide treatment decisions.

Further research is needed to evaluate the cost-effectiveness of combination therapies and to identify the optimal treatment strategies for diverse fibromyalgia patient populations.